Another study by Tortola et al. (2016) also reported the correlation between TP53 mutations alone or in combination with KRAS mutations, with poor outcomes in CRC patients, although they did not recommend the routine use of these mutations as prognostic markers in clinics [6]. This evidence concerns the gene KRAS and colorectal carcinoma.